By 2010, liraglutide (under the brand name Victoza) was approved for type 2 diabetes, becoming the first long-acting GLP-1 analog in the world
The medication should be injected subcutaneously into fatty tissue of the abdomen, thigh, or upper arm, with the abdomen often being preferred due to consistent absorption and ease of access
Wegovy side effects are often most noticeable: during the first days or weeks of treatment after increasing the dose when restarting treatment Digestive side effects such as nausea, vomiting, diarrhea, constipation, and stomach pain are usually more common early in treatment and may improve over time
C15:0 Deficiency With the discovery of C15:0 came the additional discovery that approximately one in three people globally may not be getting enough of it
Again, bear in mind that the choice between these medications often depends on individual patient factors, healthcare provider recommendations, and specific health goals